Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

315 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and tolerability of the hexanic extract of Serenoa repens compared to tamsulosin in moderate-severe LUTS-BPH patients.
Alcaraz A, Rodríguez-Antolín A, Carballido-Rodríguez J, Castro-Díaz D, Medina-Polo J, Fernández-Gómez JM, Ficarra V, Palou J, Ponce de León Roca J, Angulo JC, Esteban-Fuertes M, Cózar-Olmo JM, Pérez-León N, Molero-García JM, Fernández-Pro Ledesma A, Brenes-Bermúdez FJ, Manasanch J. Alcaraz A, et al. Among authors: angulo jc. Sci Rep. 2021 Sep 29;11(1):19401. doi: 10.1038/s41598-021-98586-5. Sci Rep. 2021. PMID: 34588509 Free PMC article.
[Randomized comparative study for the assessment of a new therapeutic schedule of fosfomycin trometamol in postmenopausal women with uncomplicated lower urinary tract infection].
Palou J, Angulo JC, Ramón de Fata F, García-Tello A, González-Enguita C, Boada A, Sanz M; en representación de los investigadores del ensayo clínico MONE-14. Palou J, et al. Among authors: angulo jc. Actas Urol Esp. 2013 Mar;37(3):147-55. doi: 10.1016/j.acuro.2012.06.007. Epub 2012 Sep 17. Actas Urol Esp. 2013. PMID: 22995326 Clinical Trial. Spanish.
Efficacy and safety of a hexanic extract of Serenoa repens (Permixon® ) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies.
Vela-Navarrete R, Alcaraz A, Rodríguez-Antolín A, Miñana López B, Fernández-Gómez JM, Angulo JC, Castro Díaz D, Romero-Otero J, Brenes FJ, Carballido J, Molero García JM, Fernández-Pro Ledesma A, Cózar Olmos JM, Manasanch Dalmau J, Subirana Cachinero I, Herdman M, Ficarra V. Vela-Navarrete R, et al. Among authors: angulo jc. BJU Int. 2018 Dec;122(6):1049-1065. doi: 10.1111/bju.14362. Epub 2018 Jun 6. BJU Int. 2018. PMID: 29694707 Free article.
Clinical Benefit of Tamsulosin and the Hexanic Extract of Serenoa Repens, in Combination or as Monotherapy, in Patients with Moderate/Severe LUTS-BPH: A Subset Analysis of the QUALIPROST Study.
Alcaraz A, Rodríguez-Antolín A, Carballido-Rodríguez J, Castro-Díaz D, Esteban-Fuertes M, Cózar-Olmo JM, Ficarra V, Medina-López R, Fernández-Gómez JM, Angulo JC, Medina-Polo J, Brenes-Bermúdez FJ, Molero-García JM, Fernández-Pro-Ledesma A, Manasanch J, The Qualiprost Study Group OBO. Alcaraz A, et al. Among authors: angulo jc. J Clin Med. 2020 Sep 9;9(9):2909. doi: 10.3390/jcm9092909. J Clin Med. 2020. PMID: 32917008 Free PMC article.
Efficacy and Safety of the Hexanic Extract of Serenoa repens vs. Watchful Waiting in Men with Moderate to Severe LUTS-BPH: Results of a Paired Matched Clinical Study.
Alcaraz A, Gacci M, Ficarra V, Medina-Polo J, Salonia A, Fernández-Gómez JM, Ciudin A, Castro-Díaz D, Rodríguez-Antolín A, Carballido-Rodríguez J, Cózar-Olmo JM, Búcar-Terrades S, Pérez-León N, Brenes-Bermúdez FJ, Molero-García JM, Ledesma AF, Herdman M, Manasanch J, Angulo JC, Group OBOTQS. Alcaraz A, et al. Among authors: angulo jc. J Clin Med. 2022 Feb 12;11(4):967. doi: 10.3390/jcm11040967. J Clin Med. 2022. PMID: 35207238 Free PMC article.
Efficacy and Tolerability of 6-Month Treatment with Tamsulosin Plus the Hexanic Extract of Serenoa repens versus Tamsulosin Plus 5-Alpha-Reductase Inhibitors for Moderate-to-Severe LUTS-BPH Patients: Results of a Paired Matched Clinical Study.
Alcaraz A, Castro-Díaz D, Gacci M, Salonia A, Ficarra V, Carballido-Rodríguez J, Rodríguez-Antolín A, Medina-Polo J, Fernández-Gómez JM, Cózar-Olmo JM, Búcar-Terrades S, Pérez-León N, Brenes-Bermúdez FJ, Molero-García JM, Fernández-Pro-Ledesma A, Herdman M, Angulo JC, Manasanch J, On Behalf Of The Qualiprost Study Group. Alcaraz A, et al. Among authors: angulo jc. J Clin Med. 2022 Jun 22;11(13):3615. doi: 10.3390/jcm11133615. J Clin Med. 2022. PMID: 35806900 Free PMC article.
Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial.
Angulo JC, Álvarez-Ossorio JL, Domínguez-Escrig JL, Moyano JL, Sousa A, Fernández JM, Gómez-Veiga F, Unda M, Carballido J, Carrero V, Fernandez-Aparicio T, García de Jalón Á, Solsona E, Inman B, Palou J. Angulo JC, et al. Eur Urol Oncol. 2023 Feb;6(1):58-66. doi: 10.1016/j.euo.2022.10.008. Epub 2022 Nov 23. Eur Urol Oncol. 2023. PMID: 36435738 Clinical Trial.
Dutasteride treatment over 2 years delays prostate-specific antigen progression in patients with biochemical failure after radical therapy for prostate cancer: results from the randomised, placebo-controlled Avodart After Radical Therapy for Prostate Cancer Study (ARTS).
Schröder F, Bangma C, Angulo JC, Alcaraz A, Colombel M, McNicholas T, Tammela TL, Nandy I, Castro R. Schröder F, et al. Among authors: angulo jc. Eur Urol. 2013 May;63(5):779-87. doi: 10.1016/j.eururo.2012.11.006. Epub 2012 Nov 12. Eur Urol. 2013. PMID: 23176897 Free article. Clinical Trial.
315 results